Streetbeat News

Stock Prices

AFYA

Afya reported Q3 earnings of $0.21 per share, down from $0.24 YoY. Quarterly sales were $148.23K, significantly missing the $140.74M estimate and representing a 99.87% decrease from $110.83M in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:24 pm

RVYL

RYVYL projects its Q4 2023 revenue to be between $19M and $21M, surpassing the estimated $17M.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:23 pm

ELAN

Piper Sandler analyst David Westenberg has maintained a Neutral rating on Elanco Animal Health (NYSE:ELAN) and increased the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:22 pm

GRND

Grindr has updated its FY23 outlook, projecting revenue growth to exceed 31%. The company also anticipates a year-over-year growth of over 25% for Q4.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 9:21 pm

ELUT

Elutia (NASDAQ:ELUT) reported Q3 earnings with an EPS of $-0.5, beating estimates by 7.41% but with a revenue decrease of $6.26 million YoY. Despite missing EPS last quarter, the stock increased by 6.72% the following day. Historical earnings show variability in performance.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 9:20 pm

CLSD

Clearside Biomedical (NASDAQ:CLSD) reported Q3 earnings with an EPS of $-0.15, which was in line with estimates. Revenue increased by $593 thousand compared to the same period last year. The company's stock price dropped 6.6% the day after missing EPS estimates last quarter.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 9:20 pm

AWH

Aspira Womens Health (NASDAQ:AWH) reported Q3 earnings with an EPS of $-0.48, beating estimates by 5.88% against an expected $-0.51. Revenue increased by $145 thousand compared to the same period last year. Despite beating EPS estimates last quarter, AWH's stock dropped by 7.61% the following day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 9:20 pm

SPRO

Spero Therapeutics (NASDAQ:SPRO) reported Q3 earnings with an EPS of $-0.06, missing estimates by 100% compared to the expected $-0.03. Revenue increased by $23.47 million from the same period last year. In the previous quarter, SPRO beat EPS estimates but the share price fell by 3.45% the following day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 9:20 pm

SPRO

Spero Therapeutics (NASDAQ:SPRO) reported a Q3 EPS loss of $(0.06), which did not meet the expected $(0.03) estimate, marking a 100% miss. However, the company saw a significant increase in sales, reporting $25.47M against the $14.97M estimate, a 70.16% beat and a 1.17K% increase from the previous year's sales of $2.01M.

Portfolio Pulse from bharat@benzinga.com

November 13, 2023 | 9:19 pm

AWH

Aspira Womens Health (NASDAQ:AWH) reported Q3 EPS of $(0.48), surpassing the $(0.51) estimate, but sales of $2.22M fell short of the $2.91M estimate. The EPS shows a 20% improvement, while sales increased by 7% compared to the same period last year.

Portfolio Pulse from bharat@benzinga.com

November 13, 2023 | 9:18 pm